Calprotectin as new potential clinical marker for multiple myeloma

Area of Science:

• Gastroenterology
• Oncology
• Clinical Chemistry

Background:

• Inflammation is increasingly recognized in multiple myeloma (MM) pathogenesis.
• Fecal calprotectin (CP) is a potential non-invasive biomarker for inflammation.

Purpose of the Study:

• To quantitatively evaluate fecal calprotectin (CP) as a non-invasive biomarker for inflammation in multiple myeloma (MM) patients.
• To compare CP levels in new MM cases, treated MM patients, and healthy controls.

Main Methods:

• A hospital-based case-control study involving new MM patients (n=40), treated MM patients (n=28), and healthy controls (n=25).
• Measurement of fecal calprotectin (CP) using the ELISA method in stool samples.
• Statistical analysis to compare CP levels between groups and correlate with clinical factors.

Main Results:

• Significant differences in mean CP levels were observed across all groups (p=0.001).
• New MM cases (301.3 μg/g) and treated MM patients (165.1 μg/g) showed significantly higher CP levels than controls (36.9 μg/g).
• CP levels positively correlated with patient age and plasma cell counts.

Conclusions:

• Quantitative fecal calprotectin (CP) is a promising non-invasive biomarker for assessing inflammation in multiple myeloma (MM).
• Inflammation is a key feature in MM, and CP can aid in clinical evaluation.
• Further diagnostic studies are recommended to explore the full potential of CP in MM management.